CRISPR Therapeutics AG Quarterly Nonoperating Income (Expense) in USD from Q3 2015 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
Summary
CRISPR Therapeutics AG quarterly/annual Nonoperating Income (Expense) history and growth rate from Q3 2015 to Q3 2024.
  • CRISPR Therapeutics AG Nonoperating Income (Expense) for the quarter ending September 30, 2024 was $25.1M, a 21.3% increase year-over-year.
  • CRISPR Therapeutics AG Nonoperating Income (Expense) for the twelve months ending September 30, 2024 was $95.9M, a 51.5% increase year-over-year.
  • CRISPR Therapeutics AG annual Nonoperating Income (Expense) for 2023 was $71.8M, a 217% increase from 2022.
  • CRISPR Therapeutics AG annual Nonoperating Income (Expense) for 2022 was $22.7M, a 277% increase from 2021.
  • CRISPR Therapeutics AG annual Nonoperating Income (Expense) for 2021 was $6M, a 5.89% decline from 2020.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Quarterly (USD)
Nonoperating Income (Expense), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $95.9M $25.1M +$4.39M +21.3% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-05
Q2 2024 $91.5M $26.1M +$7.73M +42% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-05
Q1 2024 $83.8M $24.7M +$12M +94% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-08
Q4 2023 $71.8M $20M +$8.51M +74% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-21
Q3 2023 $63.3M $20.7M +$13.4M +185% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-05
Q2 2023 $49.9M $18.4M +$14.9M +419% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-05
Q1 2023 $35M $12.7M +$12.4M +3410% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-08
Q4 2022 $22.7M $11.5M +$9.29M +423% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-21
Q3 2022 $13.4M $7.26M +$6.16M +560% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-06
Q2 2022 $7.21M $3.54M +$2.79M +373% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-07
Q1 2022 $4.41M $363K -$1.59M -81.4% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-08
Q4 2021 $6M $2.2M +$1.62M +282% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-21
Q3 2021 $4.38M $1.1M +$941K +588% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-01
Q2 2021 $3.44M $750K -$662K -46.9% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-08
Q1 2021 $4.1M $1.96M -$2.28M -53.8% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-09
Q4 2020 $6.38M $575K -$19M -97.1% Oct 1, 2020 Dec 31, 2020 10-K 2023-02-21
Q3 2020 $25.4M $160K +$626K Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-03
Q2 2020 $24.7M $1.41M +$43K +3.14% Apr 1, 2020 Jun 30, 2020 10-Q 2021-07-29
Q1 2020 $24.7M $4.23M +$4.13M +4132% Jan 1, 2020 Mar 31, 2020 10-Q 2021-04-27
Q4 2019 $20.6M $19.6M +$21.7M Oct 1, 2019 Dec 31, 2019 10-K 2022-02-15
Q3 2019 -$1.13M -$466K +$676K +59.2% Jul 1, 2019 Sep 30, 2019 10-Q 2020-10-28
Q2 2019 -$1.8M $1.37M +$2.37M Apr 1, 2019 Jun 30, 2019 10-Q 2020-07-27
Q1 2019 -$4.17M $100K +$1.32M Jan 1, 2019 Mar 31, 2019 10-Q 2020-04-28
Q4 2018 -$5.49M -$2.13M -$1.72M -417% Oct 1, 2018 Dec 31, 2018 10-K 2021-02-16
Q3 2018 -$3.77M -$1.14M -$712K -166% Jul 1, 2018 Sep 30, 2018 10-Q 2019-10-28
Q2 2018 -$3.06M -$998K -$332K -49.9% Apr 1, 2018 Jun 30, 2018 10-Q 2019-07-29
Q1 2018 -$2.73M -$1.22M -$765K -169% Jan 1, 2018 Mar 31, 2018 10-Q 2019-04-29
Q4 2017 -$1.96M -$412K -$43.2M -101% Oct 1, 2017 Dec 31, 2017 10-K 2020-02-12
Q3 2017 $41.3M -$430K -$354K -466% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-07
Q2 2017 $41.6M -$666K -$60K -9.9% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-07
Q1 2017 $41.7M -$452K -$3.74M -114% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-08
Q4 2016 $45.4M $42.8M Oct 1, 2016 Dec 31, 2016 10-K 2019-02-25
Q3 2016 -$76K -$77K Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-08
Q2 2016 -$606K Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-10
Q1 2016 $3.29M Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-11
Q3 2015 $1K* Jul 1, 2015 Sep 30, 2015 10-Q 2016-11-22
* An asterisk sign (*) next to the value indicates that the value is likely invalid.